Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Neurocrine Biosciences (NBIX) is trading at $142.39, up 0.38% on the day. Its market value of $14.47B makes it the 693rd largest of the 800 companies we follow.
The stock's 52-week band runs $122.14 to $186.12, and the latest print sits 23.5% under the top end of it.
Valuation works out to 20.8 times trailing earnings. The median for its industry group is 30.5.
24 analysts follow the stock and the average call is "buy". The mean target, $209.96, sits 47.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
24 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
NBIX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $209.96, 47.5% above today’s price, with a consensus rating of Buy.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 20.8x earnings, NBIX looks about mid-pack against the market, and trades 32% below the 30.5x median among Drug Manufacturers - Specialty & Generic names. The two comparisons do not always agree.
$142.39 is the latest print for NBIX, a move of +0.38% against yesterday's close of $141.84. Today's low and high so far: $140.54 and $143.01.
Equity value comes to $14.47B at the current price. By that measure it is number 693 of the 800 names in our coverage.
Buyers pay 20.8 times the last twelve months of profit (EPS $4.67).
The year's floor is $122.14 and the ceiling $186.12. Shares are 23.5% away from that ceiling.
Our data shows no dividend paid by Neurocrine Biosciences over the trailing twelve months.
Of 24 analysts, 88% say buy, 13% hold and 0% sell. Price targets average $209.96, with the most cautious at $165.00 and the most optimistic at $253.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on NBIX.